SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-05-29
👔
Spyre Therapeutics, Inc.
@SYRE_InsiderForm 4 Filing: Kiselak Tomas Acquires (Grant) shares of $SYRE
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
Spyre Therapeutics, Inc.
Ticker: $SYRE
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-05-27
Shares: 8,026
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Kiselak Tomas, holds the title of Director at Spyre Therapeutics, Inc..
On 2026-05-27, the insider transacted 8,026 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Kiselak Tomas (Director) was granted $0 of $SYRE
Post-Transaction Position: 8,026 shares
SEC Accession No: 0001636282-26-000069 (CIK: 1830177)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.